Pfizer Inc. (NYSE:PFE) Shares Sold by Capital Investment Counsel Inc

Capital Investment Counsel Inc trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,349 shares of the biopharmaceutical company’s stock after selling 1,433 shares during the period. Capital Investment Counsel Inc’s holdings in Pfizer were worth $878,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Heartland Bank & Trust Co lifted its holdings in shares of Pfizer by 8.3% in the 3rd quarter. Heartland Bank & Trust Co now owns 23,068 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,777 shares during the period. McAdam LLC lifted its holdings in shares of Pfizer by 13.9% in the 3rd quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 2,628 shares during the period. Guidance Capital Inc. lifted its holdings in shares of Pfizer by 2.1% in the 3rd quarter. Guidance Capital Inc. now owns 34,886 shares of the biopharmaceutical company’s stock valued at $1,019,000 after buying an additional 706 shares during the period. Greenleaf Trust lifted its holdings in shares of Pfizer by 4.2% in the 3rd quarter. Greenleaf Trust now owns 297,265 shares of the biopharmaceutical company’s stock valued at $8,603,000 after buying an additional 11,935 shares during the period. Finally, Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Pfizer by 16.1% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 397,385 shares of the biopharmaceutical company’s stock valued at $11,500,000 after buying an additional 55,024 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.

Pfizer Stock Performance

NYSE PFE opened at $28.86 on Thursday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The stock has a market cap of $163.54 billion, a price-to-earnings ratio of -481.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The business has a fifty day moving average of $29.07 and a 200-day moving average of $28.48. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the firm posted $0.67 earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.82%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.